Genexine, Inc.

Equities

A095700

KR7095700001

Biotechnology & Medical Research

End-of-day quote Korea S.E. Other stock markets 18:00:00 2024-07-04 EDT			5-day change	1st Jan Change
6,430 ^KRW	+1.42%		+3.54%	-35.05%

07-04	Genexine, Inc. Appoints Jaehyun Choi as Head of R&D	CI
06-26	Genexine, Inc. signed a letter of intent to acquire EPD Biotherapeutics Inc. for KRW25.6 billion.	CI

Genexine, Inc. signed a letter of intent to acquire EPD Biotherapeutics Inc. for KRW25.6 billion.

June 25, 2024

Genexine, Inc. (KOSDAQ:A095700) signed a letter of intent to acquire EPD Biotherapeutics Inc. for KRW25.6 billion on June 26, 2024. The transaction is subject to approval of offer by acquirer shareholders and approval of offer by acquirer board. The expected completion of the transaction is October 1, 2024.

Latest news about Genexine, Inc.

Genexine, Inc. Appoints Jaehyun Choi as Head of R&D	07-04	CI
Genexine, Inc. signed a letter of intent to acquire EPD Biotherapeutics Inc. for KRW25.6 billion.	06-25	CI
Genexine, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-14	CI
Genexine, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-14	CI
Genexine, Inc. and PT Kalbe Genexine Biologics Receives the First Market Approval for Novel Long-Acting Erythropoietin, Efepoetin Alfa, from the Indonesian Food and Drug Authority	23-10-23	CI
Sector Update: Health Care Stocks Edge Higher Premarket Thursday	23-08-31	MT
Sector Update: Health Care	23-08-31	MT
Salesforce Earnings, Inflation Outlook Bolster Exchange-Traded Funds, Equity Futures Premarket Thursday	23-08-31	MT
I-Mab's Phase 3 Trial of Growth Hormone Deficiency Drug Meets Primary Endpoint, Joint Venture Partner Says	23-08-31	MT
Genexine Announces Positive Topline Results from the Multi-Center, Randomized, Open-Label, Active-Controlled Pivotal Phase 3 Study	23-08-30	CI
Henlius Biotech Grants Hansizhuang License to Kalbe Genexine Biologics	23-08-28	MT
Genexine, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14	CI
Genexine, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15	CI
Genexine, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-20	CI
Genexine Receives Fast Track Designation from Korean Health Authority for Its Promising DNA Vaccine for Advanced Cervical Cancer	23-01-20	CI
Genexine, Inc. to Present Final Phase 2 Clinical Data on Its Cervical Cancer Program Showing a 35.0% Overall Response Rate and Provide a Corporate Overview During JP Morgan Conference	23-01-08	CI
Genexine, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-14	CI
Genexine to Raise $70 Million via Share Issuance	22-09-26	MT
Genexine’s Announces that DNA Vaccine Shows Significant Potential to Extend Survival in Late-Stage Cervical Cancer	22-09-07	CI
Genexine to Present Phase 2 Study of GX-188E in Combination with KEYTRUDA® (pembrolizumab) in Cervical Cancer at European Society for Medical Oncology Congress 2022	22-08-25	CI
Genexine Announces Dosing of First Patient in Phase 2 clinical trial with Triple Combination Therapy in Patients with Head and Neck Squamous Cell Carcinoma	22-08-17	CI
I-Mab Completes Enrollment in China Phase 3 Trial of Eftansomatropin Alfa in Pediatric Growth Hormone Deficiency	22-06-14	MT
Genexine Announces Completion of Enrollment in Phase 3 Clinical Trial with Its Proprietary Long-acting Growth Hormone, GX-H9/TJ101 (Eftansomatropin alfa)	22-06-14	CI
Genexine Reports Encouraging Top-Line Results of the Phase 1B/2 Clinical Trial with GX-I7 (Efineptakin Alfa) in Refractory or Recurrent (R/R) Metastatic Triple Negative Breast Cancer	22-06-07	CI
Genexine Appoints Neil Warma as Chief Executive Officer to Accelerate Global Growth, Product Commercialization and Innovation	22-05-24	CI

Chart Genexine, Inc.

Duration

Period

More charts

Company Profile

Genexine Inc is a Korea-based company mainly engaged in the research and development of bio pharmaceuticals. The Company operates its business through two segments. The New Drug Development segment engages in human growth hormone, neutropenia treatment, anemia treatment, anticancer immunotherapy, hyFc platform, and other technology transfers. In addition, this segment sells the technical property rights of follicle-stimulating hormone. It also engages in cell line construction and sample production, project development, animal testing, human growth hormone development, and government agency research. The Medical Consumables segment produces and sells medical consumables such as medicine bags.

Sector

Biotechnology & Medical Research

Calendar

2024-08-12 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
GENEXINE, INC.	-35.05%	193M
VERTEX PHARMACEUTICALS INCORPORATED	+16.61%	122B
REGENERON PHARMACEUTICALS, INC.	+17.75%	112B
ARGENX SE	+18.43%	25.91B
BIONTECH SE	-24.11%	19.33B
GENMAB A/S	-17.89%	16.17B
BEIGENE, LTD.	-18.47%	15.6B
WUXI APPTEC CO., LTD.	-47.75%	14.65B
SAREPTA THERAPEUTICS, INC.	+57.35%	14.34B
NEUROCRINE BIOSCIENCES, INC.	+5.62%	14B

Bio Therapeutic Drugs